As a result, pretreatment of the compound markedly reduced both intracellular and extracellular melanin levels by suppressing tyrosinase activity in α-MSH-induced B16F10 melanoma cells, demonstrating that its cellular tyrosinase inhibition was responsible for anti-melanogenic potential. Here, STAMBP is linked to melanoma.